We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury

By LabMedica International staff writers
Posted on 08 Jan 2025

Drug-induced kidney injury, also known as nephrotoxicity, is a frequent complication in clinical medicine, occurring when drugs damage the kidneys. More...

This can result from various medications, including anti-inflammatory, antibacterial, antiretroviral, and chemotherapeutic drugs, and may lead to the discontinuation or restriction of treatment. Current biomarkers are often too slow to detect early signs of kidney damage. Researchers have now identified six new biomarkers that could enable quicker and more sensitive detection of kidney injury, paving the way for safer drug development and better patient outcomes. Early detection of kidney damage could allow clinicians to intervene sooner, potentially reducing long-term harm and improving patient health in diverse medical settings.

These newly discovered biomarkers, identified by researchers at Boston Medical Center (Boston, MA, USA), may offer a more sensitive approach compared to current standards for monitoring kidney health, leading to more tolerable treatment options. The research team analyzed urinary protein biomarkers in both healthy volunteers and patients being treated for mesothelioma with a chemotherapy drug known to be toxic to the kidneys. The six biomarkers they identified are primarily produced by the kidneys in response to injury or inflammation, enabling faster detection of kidney injury than traditional blood tests like serum creatinine, which can take days to show abnormal levels. The research team now aims to explore whether these biomarkers can be applied more broadly for monitoring kidney health in clinical trials.

"These biomarkers, which can be measured in the urine, could help clinicians detect kidney damage within 24 hours of injury, enabling more timely monitoring during drug development and better treatment of patients who are at risk in clinical settings," said Sushrut Waikar, MD, MPH, first author on the paper published in Clinical Pharmacology & Therapeutics. "These biomarkers have the potential to make a real difference in how we monitor kidney health and manage patients at risk for kidney damage. We are hopeful that these findings will contribute to better strategies for preserving kidney function and improving patient care, as well as advancing safer drug development."


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.